Compare OPTX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTX | ARMP |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | 159 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.0M | 295.5M |
| IPO Year | N/A | 1996 |
| Metric | OPTX | ARMP |
|---|---|---|
| Price | $11.35 | $7.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.4M | 62.6K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.74 |
| 52 Week High | $13.75 | $14.98 |
| Indicator | OPTX | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 35.68 |
| Support Level | $5.93 | $7.22 |
| Resistance Level | $11.83 | $7.93 |
| Average True Range (ATR) | 1.69 | 0.79 |
| MACD | 0.29 | 0.00 |
| Stochastic Oscillator | 67.86 | 11.31 |
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.